CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncodesign SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncodesign SA
18 rue Jean Mazen
Phone: +33 380788260p:+33 380788260 DIJON, 21000  France Fax: +33 380788261f:+33 380788261

On 11/24/2022, the Company was acquired by Cancer Buster Bidco SAS.
This company is no longer actively traded on any major stock exchange.

Business Summary
Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its activities include preclinical evaluation services and discovery operations. The Company's technologies include Predict, Chi-Mice, Pharm'Image and Nanocyclix. Its technological platform offers solutions for pharmaceutical and biotechnology companies.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202212/31/2018Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Founder PhilippeGenne 1/1/1995 1/1/1995
Member of the Management Committee and Deputy Chief Executive Officer, Chief Scientific Officer, He JanHoflack 59 6/2/2010 1/1/2010
Member of the Management Committee and Deputy Chief Executive Officer, Director CatherineGenne
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ZoBio B.V. J.H. Oortweg 19 Leiden Netherlands

Business Names
Business Name
ALONC
François Hyafil Research Centre
ZoBio B.V.

General Information
Number of Employees: 236 (As of 12/31/2021)
Outstanding Shares: 6,848,412 (As of 12/31/2021)
Stock Exchange: EPA
Fax Number: +33 380788261
Email Address: info@oncodesign.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, June 25, 2024